Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 9/20 | 0.55 |
| ▸ | RAB9A | P51151 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505190 | 0.86 | KMO (0.61) | PRKDCALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL1429971 | 0.80 | NPC1 (0.60) | ALDH1A1HPGDKDM4EMAPTHSD17B10 | |
| SCHEMBL1505310 | 0.80 | NPC1 (0.65) | ALDH1A1HPGDKDM4EMAPTHSD17B10 | |
| SCHEMBL4250883 | 0.79 | KMO (0.68) | PRKDCMRGPRX4ALDH1A1HPGDMAPT | |
| SCHEMBL4357869 | 0.78 | KMO (0.67) | PRKDCMRGPRX4ALDH1A1HPGDMAPT | |
| SCHEMBL967418 | 0.78 | SMN1; SMN2 (0.56) | ALDH1A1HPGDKDM4EMAPTHSD17B10 | |
| SCHEMBL1505363 | 0.78 | NPC1 (0.53) | ALDH1A1HPGDKDM4EMAPTHSD17B10 | |
| SCHEMBL969326 | 0.78 | SMN1; SMN2 (0.56) | ALDH1A1HPGDKDM4EMAPTHSD17B10 | |
| SCHEMBL13780884 | 0.78 | NPC1 (0.53) | ALDH1A1HPGDKDM4EMAPTHSD17B10 | |
| SCHEMBL12171906 | 0.78 | NPC1 (0.62) | PRKDCALDH1A1HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1815206-B1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2939674-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2311455-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301536-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301538-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1815206-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044456-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | PRKDC 1503/4885MRGPRX4 4141/4885ALDH1A1 3402/4885 |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | NSUN2, UPF1, NSUN3 | PRKDC 1503/4885MRGPRX4 4141/4885ALDH1A1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.